PATENT CLAIM ANALYSIS

Application Number: 15875031
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "243000"]

Abstract:
Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

Claim (Index 29):
The method of  claim 16 , wherein the compound of formula (I) in step (c) is administered continuously.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 1.76667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14777873', '14419256', '15160729', '13799706', '14441750']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.801586234351085
- 35 USC 102 Novelty (BERT): 0.5318216254331471
- Combined Prediction Score: 0.7746097734592913
- Mean Citation Score: 283.942934
- Max Citation Score: 324.6595
- Similarity Product: 178.90272970321774

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test